BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT
Bio-Techne (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement with Waters to enhance biotherapeutic characterization and development processes.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has announced a strategic co-marketing and co-promotion agreement with Waters to enhance biotherapeutic characterization and development processes. The partnership combines Bio-Techne's MauriceFlex™ System for charge separation with Waters' BioAccord™ LC-MS System for liquid chromatography mass spectrometry.
The collaboration has already yielded joint activities in late 2024, including an application note, webinar, and presentations at major conferences such as CASSS MS, Festival of Biologics, and PEGS EU. Scientists from both companies are currently working on analyzing additional biomolecule classes, with plans to showcase results at upcoming scientific conferences through various formats including application notes and webinars.
Positive
- Strategic partnership with Waters enhances product offering in biotherapeutic characterization
- Expansion of market reach through combined expertise and technologies
- Active collaboration demonstrated through multiple scientific presentations and publications
Negative
- None.
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was -0.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Scientists and commercial team members from both companies participated in several joint activities in October and November 2024, including the publication of an application note, a webinar, poster presentations, and talks at key conferences including CASSS MS, Festival of Biologics and PEGS EU, and in-person talks at two Bio-Techne User Group Meetings in
"We are thrilled to see how these new workflows are accelerating biotherapeutic characterization in biopharma labs," said Will Geist, President of the Protein Sciences Segment at Bio-Techne. "Our goal is to continue offering innovative solutions that empower scientists, streamline workflows, and help bring life-saving therapies to market faster."
Explore Bio-Techne's automated biotherapeutic characterization platforms here.
Learn about Waters innovative analytical solutions here.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
BioAccord is a trademark of Waters Technologies Corporation.
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-biotherapeutic-characterization-strategic-co-marketing-and-co-promotion-agreement-302335808.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.